WuXi Biologics, a Shanghai CRO/CMO, opened a joint laboratory with Pall Corporation, a filtration/purification specialist, to lower the cost of making monoclonal antibodies by improving continuous processing techniques. The 3-year project aims to lower the cost of manufacturing mAbs significantly — to $5/g. Initially, the companies will focus on continuous operation of individual processes. Ultimately, they will work on optimizing downstream processing development and production.
Source: China Biotoday
